Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daridorexant in pediatric insomnia disorder
NCT05423717Phase 2
Key facts
- Status
- Completed
- Start
- Sep 2022
- Primary completion
- Jan 2026
- Countries
- 6
- Sponsor
- Idorsia
- Modality
- Small Molecules
- Drugs
- daridorexant
- Conditions
- insomnia disorder
01
Overview
Phase 2, randomised, double-blind trial of daridorexant in insomnia disorder (4 arms), sponsored by Idorsia. Primary endpoint: Total Sleep Time at Day 1. Started Sep 2022; status: completed.
02
Design
4 arms- Study design
- RandomizedDouble-blind
Daridorexant 10 mg
Daridorexant 25 mg
Daridorexant 50 mg
Placebo
03
Who it enrols
Pediatric subjects (10-17 years) with chronic insomnia disorder (ICSD-3 or DSM-5) for at least 3 months, weighing at least 25 kg, and without other sleep-wake disorders or significant unstable medical conditions.
04
Endpoints
Primary
Total Sleep Time
05
Results
Primary endpoints met
Beyond the preview
Go deeper on NCT05423717.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05423717.